Rate of redevelopment of hypertension after cessation of therapy: Relation to cardiac structure and duration of therapy  by Sudhir, Krishnankutty et al.
178A ABSTRACTS JAW Vol. 17. No. 2 February lWI:l78A 
430 
RATE OF REDEVELOPMENT OF HYPERTEhSION AFTER 
CESSATION OF THERAPY: RELATION TO CARDIAC 
STRUCTURE AND DURATION OF THERAPY. 
u-v SUM Garry Jennings, Eljas LauPer, 
Christopher Reid, Paul ‘Korner. Baker Medical Research 
Institu!e, Melbourne, Victoria, Australia. 
We studied the redevelopment of hypertension in 49 
;ratients. whose antihypertensive therapy was withdrawn. 
Mean duration of therapy was 4 years (range l-20); BP was 
well controlled (c140/90) in all patients for at least 9 months 
prior IO slopping therapy. Patients were on diuretic, beta- 
antagonist, calcium antagonist, alpha) -antagonist or 
convcrtine enzvme inhibitor therapy, or a combination of 
$ese- ag&ts. &erall, supine systolic BP redeveloped twice 
as raaidlv as supine diastolic BP (pcO.05). Al 10 weeks after 
stoppkg s therapy’, 33% of patients were normotensive wi!h 
DBPs <90 mmHg. These patients had a lower left ventricular 
wall thickness (1.07f0.04 cm), and a lower cardiac oulpul 
(5.16 I/min) at the time of cessation of lherapy than the 66% 
who redeveloped hypertension within 10 weeks (LV wall 
thickness=l.24&0.04, CO=5.9f0.18 I/min). Also, patients who 
had received anti-hypertensive therapy for more than 1 
year had a slower rate of redevelopment of hypertension 
(1.3 mmHg/werk vs. 4.3fl.lmmHg/week, p-0.05), and a 
thmner LV wall (1.1 lfO.05 vs 1.24 f0.04 cm, p=O.O4) than 
those who had been treated for 1 year. Pre-treatment blood 
pressure did not correlate with the rate of redevelopment of 
hypertension after stopping therapy. We conclude that 
redevelopment of hypertension after cessation of long-term 
therapy is characterized by a high cardiac output, and 
residual LV hypcnrophy. and relates inversely to duration 
of prior anti-hypertensive therapy. 
445 
ANTIHYPERTENSIVE THERAPY AND VENTRICULAR ARRHYTHMIAS IN 
PATIENTS WITH MODERATE-SEVERE LVH. 
, Puneet 
Notargiacomo, Ross D. Fletcher, 
Centers, Washington, D.C. 
Narayan , Aldo 
VA and Georgetown Medical 
Left ventricular hypertrophy (LVW) has been associated 
with increased ventricular ectopy and risk for sudden 
death. However studies assessing the effect of treatment 
on these arrhythmias are scarce. In the present trial 24 
pts with overt LVH (LVPW thickness 1 14 mm) underwent 
sequential treatment for 2 to 4 weeks each with placebo, 
diltiazem, metoprolol and enalapril. The sequence of 
treatment was determined using the Latin square method. 
Pts were subjected to the usual clinical evaluation, to 
48hr Holter monitoring and signal-averaged ECG (SA-ECG) 
during each phase. The following results were obtained. 
SB.’ mmHG 
Placebo Diltiazem Metoprolol Enalapril 
168 150* 150* 152* 
DBP mmHG 103 87* 89* 92* 
PVC/Pbhrs 569 232** 269** 752 
COUPL/Plhrs 5.8 3.6 4.6 17.3 
VT/24hrs 0.4 0.15 0.11. 1.14 
Lown grade 
IV,V 10 10 9 9 
* - P<O.OOl; ** - PcO.09; SBP - systolic blood pressure; 
DBP - Diastolic BP. 
SA-ECG variables (QRS,RMSOO,LAS) remained normal in all 
pts. Even pts with couplets or runs of VT had no late 
potentials on SA-ECG. We conclude:l) In pts with advanced 
LVH frequent and complex arrhythmia:: are common; 2) The 
presence of even complex arrhythmias on Holter monitoring 
(couplets or runs of VT) does not predict late potentials 
on SA-EGG and 3) Treatment with diltiazem or metoprolol 
but not enalapril resulted in a trer,d towards decreased 
ventricular arrhythmias. 
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ACUTE BLOOD PRESSURE REDUCTION CAUSES LEFT 
VENTRICULAR FUNCTIONAL NT FN 
HYPERTENSIVE PATIENTS WITH CORON DISEASE 
AND LEFTVENTRICULARHYPERTROPHY 
* John M Cruickshank, Jennifer Keegan, Rim Fox, 
Nuclear Medicine departments, Royal Bromp and 
National Heart Hospital, London, UK. 
A possible relationship exists between diastolic blood pressure (DBP) 
and death from myocardial infarction in hypertensive patients (HP). 
We examined left ventricular functional reserve in IS HP on 
beta-blockade with coronary heart disease alone, left ventricular 
hypertrophy alone, or both, when DBP was acutely lowered. Left 
ventricular hypertrophy was assessed by M-mode echocardiography. 
DBP was lowered with intravenous trimetaphan camsylate 2-12 
mg/minute and was measured via a radial-a~t~riaI line. Left 
ventricular ejection fraction was continually assessed using gated 
blood pool scanning. Resting mean left ventricular ejection fraction 
for the group was (Mean&E.M) 5153%. Mean DBP was lowered 
from 80.9k2.4 tc 61.2k2.2 mmH8. In HP with significant left 
hypertrophy alone (n-3) or HP with coronary heart 
ne (n.u7) an increase in left ventricular ejection fraction 
occurred in every case (mean rise 18.853.3%). In the 5 HP with 
combined coronary heart disease and left ventricular hypertrophy the 
left ventricular ejection fraction either fell or was unchanged, the 
mean change being -6.4% (Student’s t test, p<O.OOl). 
HP with combined coronary heart disease and left ventricular 
hypertrophy with normal resting left ventricular function exhibit 
poor LV functional reserve when DBP is lowered to below 80 mmH& 
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Notargiacomo, Barry Materson, VA Cooperative 
Bypertension Study Group and Georgetown 
University Medical Center, Washington, DC. 
Studies of drug effect on LV mass may vary due 
to design and sample size. We report short-term 
(8 wks) results of a 15 center double-blind, 
placebo-controlled, dose-titration trial of 6 
active drugs, and placebo (PLAC). In 466 men 
(av BP 152+14/99 +3mr1 Hg, av LV mass 332291 gm, 
48% black, 58%>6(3 yrs) centrally read echocar- 
diagrams were compared between: hydrochloro- 
thiazide (HCT), atenolol (ATEN), captopril 
(CAPT), clonidine (CLON), diltiazem (DILT), and 
prazosin (PBAZ). LV mass decreased only with 
CLGN (-16.927.8 gm, p=.O3) and DILT (-16.92 8.8 
gm, p=.06). Decrease in posterior (-.46+.26 mm, 
ps.08) and septal (-.71+.25 mm, p=.OO5) wall 
thickness and LV systol& size (S) (-1.03k.55 
mu, p=.O7) occurred with CLAN. However, pts on 
ATEN had increase in LV diastolic size (1.654 
0.6 mm, p=.OO8), increased LVS (1.09+.61, p= 
.08) and increase in left atria1 size (1.08+ 
.48, p=.O3). BP respcrrders (DBP I 90 mm Hg 
with therapy) did not differ in LVW response 
sponders. 
(1) LV mass regresses rapidly with 
therapy of hypertension and is not limited to 
those with "adequate" BP response, (2) Drugs 
differ in effect on LV mass regression, (3) In- 
crease in LV cavity and LA size seen only with 
ATEN suggest an early adverse effect of ATEN on 
LV geometry. 
